Synthesis and in vitro pharmacology of a series of hybrid molecules possessing 1,4-dihydropyridine calcium-channel blocking activity and histamine H2-agonistic properties

The synthesis and in vitro pharmacology of a series of new cardiovascular hybrid molecules, which could be useful for the treatment of certain types of hypertension and at the same time for the treatment of cardiac ischemic disease, are discussed. Two types of 1,4-dihydropyridine Ca2+-channel blockers have been studied. In general, hybrid molecules possessing a diethyl 2-(ω-aminoalkylthio)methyl-2,6-dimethyl-4-[(substituted)phenyl]-1,4-dihydropyridine-3,5-dicarboxylic structural moiety and a histamine H2-agonistic structural moiety are more potent L-type calcium-channel blockers and histamine H2-agonists than hybrid molecules containing a diethyl 4-[2-(ω-aminoalkoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic structural moiety

Synthesis and in vitro pharmacology of new 1,4-dihydropyridines. 1. 2-(ω-Aminoalkylthiomethyl)-1,4-dihydropyridines as potent calcium channel blockers

The synthesis and in vitro calcium channel blocking activities and binding of 2-(ω- aminoalkylthiomethyl)-4-(substituted)phenyl-1,4-dihydropyridines, by determination of the displacement of [3H]nitrendipine from the calcium channel binding sites on rat cortex have been discussed. It has been shown that increasing the alkyl chain length on the 2-position of the 1,4-dihydropyridine ring from ethyl to pentyl does not affect the calcium channel blocking activity of 3-nitrophenyl substituted dihydropyridines, measured on K+-depolarisation induced contractile responses in rat aorta strips. It did not seem to be important whether the 1,4-dihydropyridines bore 2 identical or different ester moieties on the 3- and 5-position of the 1,4-dihydropyridine ring